This registrational trial represents a major step toward potential approval and commercialization of HMPL-760. Traders should monitor enrollment progress, upcoming interim data, and any future FDA/EMA trial initiation. The absence of partnership or dilution risk (HUTCHMED retains full rights) enhances equity upside.
HCM drugs
HCM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 24 $14.12entry
- T+1 · 8mo ago +0.21%α −0.34% · $14.15
- T+5 · 8mo ago +5.95%α +6.38% · $14.96
- T+20 · 7mo ago +3.12%α −5.77% · $14.56
- T+60 · 5mo ago −27.20%α −41.52% · $10.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibitor, in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial follows promising Phase II results showing improved response and survival outcomes, positioning HMPL-760 as a potential best-in-class therapy targeting both wild-type and C481S-mutated BTK.
Key Facts
- HUTCHMED initiated a registrational Phase III trial of HMPL-760 in combination with R-GemOx for relapsed/refractory DLBCL in China.
- First patient dosed on March 20, 2026; trial is randomized, double-blind, and placebo-controlled.
- Primary endpoints are progression-free survival (PFS) and overall survival (OS); trial will enroll ~240 patients.
- Phase II data (NCT06601504) showed improved ORR, CRR, PFS, and OS with manageable safety profile.
- HMPL-760 is a non-covalent, reversible, third-generation BTK inhibitor active against C481S-mutated BTK, a key resistance mechanism.
- HUTCHMED retains global rights to HMPL-760, enabling full commercial upside.
Financial Impact
High long-term value potential if approved, given DLBCL's prevalence (~81,000 new NHL cases annually in China) and lack of effective therapies for relapsed/refractory patients.
Risk Factors
- Clinical trial may fail to confirm Phase II efficacy, particularly in PFS and OS endpoints.
- Safety issues could emerge in larger trial population.
- Regulatory delays or requirements for additional studies could prolong path to approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260096 |
Track record
33 reports on HCM
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers